ArticleIndian dermatology online journal2026
Vitamin D and its Analogs in Treatment of Mild to Moderate Alopecia Areata: Systematic Review and Meta-Analysis.
Article in Indian dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Insights into the Diagnostics and Therapeutics of Alopecia Areata-An Indian Context.Indian dermatology online journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, vitamin D3 and its analogs have shown therapeutic potential in the treatment of alopecia areata (AA). AIM AND
objectiveThe aim of this study was to evaluate the safety/efficacy of topical/intralesional vitamin D3 and its analogs for treatment of mild-to-moderate AA. MATERIALS AND
methodsWe included clinical trials that evaluated topical/intralesional vitamin D3 and its analogs for the treatment of AA. Response rates were defined as either achieving a Score 4 (S4) response on the hair regrowth scale (≥75% regrowth) or reduction in the mean Severity of Alopecia Tool (SALT) score after treatment.
resultsThe overall success rate of vitamin D3 and its analogs in the treatment of mild-to-moderate AA is about 53.75%. Both intralesional and topical vitamin D3 (odds ratio = 3.20; 95% confidence interval (CI): [1.24, 8.24] and mean difference (MD) = 2.11; 95% CI: [-1.10, 5.31], respectively) are effective in the treatment of mild-to-moderate AA. Additionally, topical vitamin D3 analogs had a synergistic effect when used in combination with other treatments including topical corticosteroids and NB-UVB (MD = 0.62; 95% CI: [-0.24, 1.48] and MD = 1.34; 95% CI: [0.96, 1.71]), respectively. Intralesional vitamin D3 showed lower efficacy compared to intralesional corticosteroid and topical bimatoprost (MD = -4.73; 95% CI: [-7.38, -2.08]). No serious adverse events were associated with the use of vitamin D3 and its analogs. LIMITATIONS: Small number of randomized clinical trials, lack of baseline vitamin D3 levels and co-morbid autoimmune conditions assessment.
conclusionVitamin D3 and its analogs may serve as a safe, inexpensive alternative for mild-to-moderate patchy AA, either as a mono-therapeutic agent or as an adjuvant for more severe cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.